Daniel Ocaña
736 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD - Global Initiative for Chronic Obstructive Lung Disease - GOLD

GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD - Global Initiative for Chronic Obstructive Lung Disease - GOLD | Daniel Ocaña | Scoop.it
Daniel Ocaña Rodriguez's insight:
Share your insight
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

High resting heart rate may signal exacerbation risk in COPD patients

Knowing the resting heart of COPD patients may predict whether they are at risk of having an exacerbation.
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Emp2016 ESC Guidelines for the management of atrial
fibrillation developed in collaboration with EACTSty title

more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Does Roflumilast Reduce COPD Exacerbations? : Cleveland Clinic Journal of Medicine

Am J Respir Crit Care Med; 2016 Sep 1; Martinez, et al
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Current asthma contributes as much as smoking to chronic bronchitis in | COPD

Current asthma contributes as much as smoking to chronic bronchitis in | COPD | Daniel Ocaña | Scoop.it

Current asthma contributes as much as smoking to chronic bronchitis in middle age: a prospective population-based study

more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

European Medicines Agency - - Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.
Daniel Ocaña Rodriguez's insight:
Otro empujoncito para romper barreras
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Access to Pulmonologists for Adults with COPD

This data emphasizes the importance of primary care in the management of respiratory disease. Primary care physicians are and will remain an important source of care for patients with COPD, and in many areas of the country, the only source of care for patients with COPD. —Neil Skolnik, MD
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice — NEJM

Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice — NEJM | Daniel Ocaña | Scoop.it
Original Article from The New England Journal of Medicine — Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Los adultos mayores de 60 años se beneficiarán en Madrid de la Vacuna VNC13

Los adultos mayores de 60 años se beneficiarán en Madrid de la Vacuna VNC13 | Daniel Ocaña | Scoop.it
La medida se toma a la vista de que el número de casos de enfermedad neumocócica registrados en población adulta >60 años en la Comunidad de Madrid sigue siendo importante, lo que justifica esta intervención directa sobre un grupo de edad para maximizar el beneficio poblacional de la vacunación infantil con la vacuna conjugada, a través de un…
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Why 10 days of antibiotics for infections is not magic

Daniel Ocaña Rodriguez's insight:

In the United States, we treat almost all infections for 10 days. Why? In France, most infections are treated for 8 days. In the U.K., most infections are treated for 5 days. In many other countries, infections are treated until symptomatic improvement occurs. Can everyone outside the United States be wrong? What is the evidence base for the various recommended durations?

more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Guideline Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

Guideline Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline | Daniel Ocaña | Scoop.it
BACKGROUND: 
COPD is a major cause of morbidity and mortality in the United States as well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in...
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults — NEJM

Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults — NEJM | Daniel Ocaña | Scoop.it
RESULTS
A total of 656 patients were included during the beta-lactam strategy periods, 739 during the beta-lactam–macrolide strategy periods, and 888 during the fluoroquinolone strategy periods, with rates of adherence to the strategy of 93.0%, 88.0%, and 92.7%, respectively. The median age of the patients was 70 years. The crude 90-day mortality was 9.0% (59 patients), 11.1% (82 patients), and 8.8% (78 patients), respectively, during these strategy periods. In the intention-to-treat analysis, the risk of death was higher by 1.9 percentage points (90% confidence interval [CI], −0.6 to 4.4) with the beta-lactam–macrolide strategy than with the beta-lactam strategy and lower by 0.6 percentage points (90% CI, −2.8 to 1.9) with the fluoroquinolone strategy than with the beta-lactam strategy. These results indicated noninferiority of the beta-lactam strategy. The median length of hospital stay was 6 days for all strategies, and the median time to starting oral treatment was 3 days (interquartile range, 0 to 4) with the fluoroquinolone strategy and 4 days (interquartile range, 3 to 5) with the other strategies.
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Alemania retira del mercado unos 80 genéricos por irregularidades en sus ensayos clínicos

BERLIN, diciembre 10: Así lo decidió el Instituto Federal de Medicamentos y Productos Médicos (BfArM), luego de una larga investigación. En su mayoría son medicamentos producidos por laboratorios indios y españoles. Si bien no hay peligro potencial para la salud, se encontró que algunos estudios, como los electrocardiogramas, fueron manipulados.
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Buenas noticias para la pioglitazona y el cáncer de vejiga urinaria

Buenas noticias para la  pioglitazona y el cáncer de vejiga urinaria | Daniel Ocaña | Scoop.it
Buenas noticias para la  pioglitazona y el cáncer de vejiga urinaria Con esto del riesgo de padecer cáncer debido a los fármaco
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease (ATS Journals)

Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease (ATS Journals) | Daniel Ocaña | Scoop.it
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Are We Too Clean or Too Dirty? The Hygiene Hypothesis in Asthma | Clinical Correlations

Are We Too Clean or Too Dirty? The Hygiene Hypothesis in Asthma | Clinical Correlations | Daniel Ocaña | Scoop.it
By James Barger Peer Reviewed Asthma, an obstructive pulmonary disease characterized by bronchospasm and chronic airway inflammation, has afflicte
Daniel Ocaña Rodriguez's insight:
No está mal la revisión realizada por este estudiante de 3º de medicina!
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Vacunas en el adulto: importancia de las inmunizaciones en población sana y en grupos de riesgo

Vacunas en el adulto: importancia de las inmunizaciones en población sana y en grupos de riesgo
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Guideline 153: British guideline on the management of asthma

Guideline 153: British guideline on the management of asthma | Daniel Ocaña | Scoop.it
British guideline on the management of asthma
Daniel Ocaña Rodriguez's insight:
Profundiza en el planteamiento de sospecha de Asma propuesto por GINA
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

Omalizumab Treatment Response in a Severe Allergic Asthma Population with Overlapping COPD

Daniel Ocaña Rodriguez's insight:
Manejo del paciente mixto... ¿nos planteamos fármacos específicos de cada una de las patologías? Montelukast...
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

El justificante médico de ausencia escolar, la historia interminable.

El justificante médico de ausencia escolar, la historia interminable. | Daniel Ocaña | Scoop.it
Hay situaciones que se repiten una y otra vez y no por ello quedan resueltas, cada profesional o grupo de profesionales actúa diferente
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

FDA approves flibanserin for low female sexual desire

FDA approves flibanserin for low female sexual desire | Daniel Ocaña | Scoop.it
The Food and Drug Administration has approved flibanserin as the first drug treatment for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug – marketed as Addyi – is expected to be available by Oct. 17.
Conditions of the drug’s third – and successful – bid for approval, however, include a risk evaluation and mitigation strategy (REMS), post-marketing research, and a boxed warning to highlight the risk of severe hypotension and syncope for some patients.
Th
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

¿Criterio de positividad de la Prueba Broncodilatadora en >8% ?

¿Criterio de positividad de la Prueba Broncodilatadora en >8% ? | Daniel Ocaña | Scoop.it
Background. 
Consensus on how best to express bronchodilator reversibility (BDR) is lacking. We tested different BDR criteria against the null hypotheses that BDR should show no sex or size bias. To determine the best criterion for defining BDR we hypothesized that clinically important BDR...
more...
No comment yet.
Scooped by Daniel Ocaña Rodriguez
Scoop.it!

INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone

Eur Respir J. 2014 Dec;44(6):1548-56. doi: 10.1183/09031936.00126814. Epub 2014 Oct 30.
more...
No comment yet.